Abstract: Systems, apparatus, articles of manufacture, and methods are disclosed for adaptive platform power management. These improve energy source management through switching energy sources of an edge node by incorporating memory, machine readable instructions, and processor circuitry to execute the functions of: evaluate operational parameters of a first energy source connected to a node and a second energy source connected to the node; determine an energy source to run a workload of the edge node based on a comparison of a first renewability to a second renewability, the evaluation of the operational parameters, and a power requirement of the workload, wherein the preferred energy source is the first energy source or the second energy source; and cause the edge node to switch to the preferred energy source.

Abstract: The current disclosure provides for novel therapeutic methods by identifying glioblastoma patient populations that may be treated effectively by immunotherapies. Also provided are therapies that may be used in combination of immune checkpoint therapy (ICB) to increase the effectiveness of the therapy. Aspects of the disclosure relate to a method of treating glioblastoma in a subject comprising administering to the subject immune checkpoint blockade (ICB) therapy after the subject has been determined to have low expression of CD73 in a biological sample from the subject.

Abstract: Aspects of the disclosure relate to a method of treating glioblastoma in a subject comprising administering to the subject a KDM6B inhibitor. In some aspects, the methods are performed in combination with an immunoterhapy. Further aspects relate to a composition comprising a KDM6B inhibitor and an immunotherapy.

Abstract: The current disclosure provides for novel therapeutic methods by identifying cancer patient populations that may be treated effectively by immunotherapies. Accordingly, aspects of the disclosure relate to a method of treating cancer in a subject comprising administering to the subject immune checkpoint blockade (ICB) therapy after the subject has been determined to have increased expression of CXCL13 in a biological sample from the subject.

Abstract: Methods and systems for controlling operation of a smelt dissolving tank receiving a flow of smelt and having a vent stack in fluid communication are provided. A dissolving liquid is injected into the smelt dissolving tank at a predetermined injection rate. A temperature of a flow of vapour in the vent stack is measured with a sensor. The injection rate of the dissolving liquid is controlled based on the temperature of the flow of vapour.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: Provided herein are mice that are heterozygous knock outs for Ctla4 and homozygous knockouts for Pdcd1 (Ctla4+/? Pdcd1?/? mice), which may suffer from autoimmunity, including myocarditis and insulin-dependent diabetes mellitus. Also provided are methods of using such mice to screen for therapeutic agents that mitigate immune-related adverse events.

Abstract: A toothbrush includes a removable, replaceable brush head that includes a clip that also serves as a removal tool for a spent brush head. The toothbrush may be a manually-wound or charged, powered toothbrush that includes a winding mechanism, an energy storage element, and an output gear train to cause a rotating, oscillating or sweeping brush head to move, thus improving the efficacy of the user's oral-care regimen.

Abstract: Methods and systems for controlling operation of a smelt dissolving tank receiving a flow of smelt and having a vent stack in fluid communication are provided. A dissolving liquid is injected into the smelt dissolving tank at a predetermined injection rate. A temperature of a flow of vapour in the vent stack is measured with a sensor. The injection rate of the dissolving liquid is controlled based on the temperature of the flow of vapour.

Abstract: Provided herein are methods for identifying a subject as a responder or non-responder to immune checkpoint blockade by detecting a B cell signature. Further provided herein are methods for treating cancer by administering immune checkpoint blockade therapy to a subject identified to have a B cell signature.

Abstract: A manually-wound or charged, powered toothbrush includes a winding mechanism, an energy storage element, and an output gear train to cause a rotating, oscillating or sweeping brush head to move, thus improving the efficacy of the user's oral-care regimen. The toothbrush may include a removable, replaceable brush head that includes a clip that also serves as a removal tool for a spent brush head.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: A method and device for detection of specific bacteria of interest by monitoring for chemical changes in media using electrical circuits. The present invention provides an inexpensive method to detect and measure particular bacteria of interest in samples, and is useful in particular as a means of monitoring for contamination in water sources.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.

Abstract: Described herein are chimeric Newcastle disease viruses engineered to express an agonist of a co-stimulatory signal of an immune cell and compositions comprising such viruses. Also described herein are chimeric Newcastle disease viruses engineered to express an antagonist of an inhibitory signal of an immune cell and compositions comprising such viruses. The chimeric Newcastle disease viruses and compositions are useful in the treatment of cancer. In addition, described herein are methods for treating cancer comprising administering Newcastle disease viruses in combination with an agonist of a co-stimulatory signal of an immune and/or an antagonist of an inhibitory signal of an immune cell.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.

Abstract: Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.